A phase 1/2 clinical trial on the safety and preliminary efficacy of a single interbody local administration in patients with degenerative disc disease undergoing interbody fusion. According to the announcement of “Anjisheng Biology”, the product intends to promote new bone formation and bone healing through the use of drugs during intervertebral fusion, thereby increasing the rate of intervertebral fusion, shortening the fusion time, and minimizing the risk and failure of patients to undergo surgery again. The necessary financial burden.
Editor: Cai Shuning